Keyword Connections

imatinib

Journals

13

1 Journal of pharmaceutical and biomedical analysis

2 British journal of clinical pharmacology

3 Cureus

4 European journal of cancer (Oxford, England : 1990)

5 Journal of medical case reports

6 clinical lymphoma, myeloma & leukemia

7 hospitals

8 Therapeutic advances in hematology

9 Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences

10 problemy radiatsiinoi medytsyny ta radiobiolohii

11 journal of the optical society of america

12 eurasian journal of medicine and oncology

13 Pharmacogenomics

Research Groups

0

No Research Group Connected

Bibliographies

43

1 The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.

2 Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.

3 Сase Report of Acute Toxic Imatinib-induced Hepatitis in a Patient with Chronic Myeloid Leukemia, Sulfa Allergy, and Rheumatoid Arthritis.

4 Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report.

5 Assessment of response to imatinib therapy in patients with chronic myeloid leukemia with e13a2 and e14a2 transcripts of BCR/ABL1 gene.

6 A visual system model and a new distortion measure in the context of image processing.

7 Drug distribution in hospitals. Unit-dose systems reduce error, increase efficeincy.

8 Ethnic Differences in Hematologic Toxicity from Imatinib in Patients with Gastrointestinal Stromal Cell Tumor (GIST): Coincidence or a Real Phenomenon.

9 sustained response of a clivus chordoma to erlotinib after imatinib failure

10 a rare presentation of chronic myeloid leukemia blast crisis

11 treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice

12 frequency of the bcr/abl rearrangements and associated alterations detected by fish during monitoring of patients taking imatinib mesylate in isolation freqüência do rearranjo bcr/abl e alterações associadas detectadas por fish no monitoramento de pacientes em uso exclusivo do mesilato de imatinibe

13 imatinib treatment reduces brain injury in a murine model of traumatic brain injury

14 tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in cml patients

15 advances and challenges on management of gastrointestinal stromal tumors

16 Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation.

17 The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure.

18 CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients.

19 UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma.

20 Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo

21 Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo

22 Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study.

23 Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.

24 Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.

25 Listeria monocytogenes Meningitis Following Imatinib Mesylate-Induced Monocytopenia in a Patient with Chronic Myeloid Leukemia

26 Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes

27 management of skin toxicity related to the use of imatinib mesylate (sti571, glivec™) for advanced stage gastrointestinal stromal tumours

28 profile of imatinib in pediatric leukemia

29 adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a brazilian hospital

30 delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity

31 importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance

32 prolonged therapy with imatinib mesylate before surgery for advanced gastrointestinal stromal tumor results of a phase ii trial

33 the effect of apigenin on pharmacokinetics of imatinib and its metabolite n-desmethyl imatinib in rats

34 low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia

35 antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-kit exon 13 missense mutation k642e

36 successful peripheral blood stem cells collection in imatinib pretreated and nilotinib-treated chronic myeloid leukemia patient

37 pharmacokinetics interaction between imatinib and genistein in rats

38 monitoração molecular da leucemia mielóide crônica na era do imatinibe molecular monitoring of chronic myeloid leukemia in the imatinib era

39 lichen planus associated with imatinib mesylate

40 sea antagonizes the imatinib-meditated inhibitory effects on t cell activation via the tcr signaling pathway

41 Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer.

42 Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?

43 Impact of and Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis.